Hematology

Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
2215-CL-0301A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 MutationLeber, Dr BrianOpenNCT02421939
INSPIREA Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating AgentLeber, Dr BrianOpenNCT02562443
M15-656A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction TherapyLeber, Dr BrianOpenNCT02993523
MCRN 004A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma.Kouroukis, Dr TomOpenNCT03215524
SGI-110-07A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating AgentsLeber, Dr BrianOpenNCT02907359
M15-550Open-label, single arm, phase 3b, multi-center study evaluating the efficacy of Venetoclax (ABT-199) in relapsed/refractory subjects with chronic lymphocytic leukemia (CLL) including those with the 17p deletion or TP53 mutation OR those who are refractory or intolerant to B-cell receptor inhibitorsLeber, Dr BrianOpenNCT02756611
LY.17A MULTI-STAGE RANDOMIZED PHASE II STUDY OF NOVEL COMBINATION THERAPY IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE B-CELL LYMPHOMAFraser, Dr GraemeOn holdNCT02436707
CINC424C2301 (REACH 2)A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantationLeber, Dr BrianOn holdNCT02953678
CINC424D2301 (REACH 3)A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH 3)Foley, Dr RonanOn holdNCT03112603
AZA-MDS-003A phase 3, multicentre, randomized, double-blind study to compare with efficacy and safety of oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red blood cell transfusion-dependent anemia and thrombocytopenia due to IPSS lower-risk myelodysplatic syndromesLeber, Dr BrianOn holdNCT01566695
Download PDF